Calcium Homeostasis and Bone-Endocrine Links - Anatomy and Physiology

SECTION 1

Historical Context & Motivation

The recognition that bone is not merely an inert scaffold but a dynamic, metabolically active tissue took well over a century to crystallize. Early anatomists viewed the skeleton as little more than structural engineering, but a series of landmark discoveries revealed that the skeleton participates in an intricate hormonal conversation with the kidneys, intestines, and parathyroid glands. Understanding calcium homeostasis — the maintenance of plasma Ca²⁺ within a narrow range of roughly 2.2–2.6 mmol/L — became essential once physiologists demonstrated that even small deviations cause tetany, cardiac arrhythmias, or coma. The history of this field therefore mirrors the broader story of how endocrinology emerged as a discipline, linking chemical messengers to distant organ responses.

1880 • Parathyroid Glands Identified

Ivar Sandström described small glandular bodies behind the thyroid in humans, although their function remained unknown for decades.

1909 • MacCallum & Voegtlin Link Parathyroids to Ca²⁺

William MacCallum and Carl Voegtlin showed that tetany following parathyroidectomy could be reversed by calcium administration, establishing the first endocrine–calcium connection.

1925 • Collip Isolates Parathyroid Hormone

James Collip prepared the first active extract of parathyroid hormone (PTH), demonstrating its ability to raise blood calcium in parathyroidectomized animals.

1961–1962 • Calcitonin Discovered

Copp and colleagues identified calcitonin from parafollicular (C) cells of the thyroid, showing it lowers blood calcium by inhibiting osteoclast activity.

1971 • Active Vitamin D Pathway Elucidated

Hector DeLuca's group characterized the renal hydroxylation step that converts 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D₃ (calcitriol), completing the hormonal triad governing calcium balance.

With these discoveries in hand, a central question emerged: How do PTH, calcitonin, and calcitriol coordinate across bone, kidney, and gut to defend the plasma calcium setpoint, and what happens at the cellular level inside bone when these hormones arrive? This lesson answers that question by tracing the feedback loops, the cellular machinery of bone remodeling, and the clinical consequences of imbalance.

SECTION 2

Core Principles & Definitions

Calcium serves roles that extend far beyond skeletal integrity. Approximately 99% of the body's calcium resides in bone as hydroxyapatite crystals (Ca₁₀(PO₄)₆(OH)₂), while the remaining 1% circulates in blood and tissues, where it is indispensable for neuromuscular excitability, coagulation cascades, second-messenger signaling, and cardiac contractility. The body therefore faces a continuous engineering problem: maintain plasma Ca²⁺ within a very tight range while also sustaining the structural reservoir that is bone. Five foundational principles govern this balancing act.

Negative Feedback Regulation

Plasma Ca²⁺ is sensed by the calcium-sensing receptor (CaSR) on parathyroid chief cells. A drop in Ca²⁺ stimulates PTH release; a rise suppresses it. This classic negative feedback loop is the master regulatory mechanism.

Three-Organ Effector System

PTH acts on three target sites — bone (mobilizing Ca²⁺ via osteoclast activation), kidneys (increasing Ca²⁺ reabsorption and calcitriol synthesis), and indirectly on the intestine (via calcitriol-driven Ca²⁺ absorption) — to raise plasma calcium.

Bone as a Dynamic Reservoir

Bone undergoes continuous remodeling — coupled cycles of osteoclast-driven resorption and osteoblast-driven formation — allowing the skeleton to release or sequester calcium on demand while repairing microdamage.

Hormonal Triad

Three hormones form the primary regulatory axis: PTH (raises Ca²⁺), calcitriol (raises Ca²⁺ via gut absorption), and calcitonin (lowers Ca²⁺ via osteoclast inhibition). Their interplay ensures minute-to-minute and day-to-day calcium balance.

Reciprocal Ca²⁺–Phosphate Relationship

Because Ca²⁺ and PO₄³⁻ form insoluble salts, their plasma concentrations are inversely coupled. PTH not only raises Ca²⁺ but also promotes renal phosphate excretion, preventing dangerous calcium-phosphate precipitation.

✦

KEY TAKEAWAY

Think of bone as a massive, well-managed savings account for calcium. The body's checking account — plasma Ca²⁺ — must never dip below a critical minimum or exceed a safe maximum. PTH acts like an automatic transfer from savings to checking when the balance runs low, calcitriol increases the direct-deposit rate from dietary intake, and calcitonin occasionally slows withdrawals. The CaSR on the parathyroid glands functions as the bank's real-time balance monitor, triggering transfers the moment funds drop.

SECTION 3

Visual Explanation — The Calcium Feedback Loop

The diagram illustrates the dual feedback loop. When plasma Ca²⁺ falls (left branch), the parathyroid glands release PTH, which acts on bone and kidney to raise Ca²⁺ and stimulates calcitriol synthesis for intestinal absorption. When plasma Ca²⁺ rises (right branch), thyroid C cells secrete calcitonin, which inhibits osteoclast-mediated bone resorption. Dashed arrows indicate the net effect on plasma calcium, completing the negative feedback loop.

Several features of this feedback architecture deserve emphasis. First, PTH secretion is essentially continuous at basal levels, with the rate modulated up or down rather than switched on or off — a graded, real-time response mediated by the CaSR. Second, calcitriol production in the kidney depends on PTH-stimulated expression of the enzyme 1α-hydroxylase, creating a feed-forward amplification: low Ca²⁺ → more PTH → more calcitriol → more intestinal Ca²⁺ absorption. Third, calcitonin's physiological importance in adult humans is debated; patients who have undergone total thyroidectomy (and therefore lack C cells) do not typically develop hypercalcemia, suggesting that PTH-mediated regulation is the dominant arm. Calcitonin nonetheless remains pharmacologically useful and is more prominent in species such as salmon, from which therapeutic preparations were historically derived.

SECTION 4

Mechanisms of Hormonal Action on Bone

PTH Signaling and Osteoclast Activation

A critical detail of PTH action is that osteoclasts — the cells responsible for bone resorption — do not themselves express PTH receptors. Instead, PTH binds the PTH1 receptor (PTH1R) on osteoblasts and osteocytes. Activated osteoblasts then upregulate expression of RANKL (receptor activator of nuclear factor κB ligand) on their surface while simultaneously downregulating secretion of osteoprotegerin (OPG), a decoy receptor that normally sequesters RANKL. The net effect shifts the RANKL/OPG ratio in favor of RANKL, which binds RANK on osteoclast precursors, driving their differentiation into mature, multinucleated osteoclasts that secrete hydrochloric acid and cathepsin K to dissolve mineral and degrade collagen, respectively.

RANKL–OPG BALANCE

Net resorption signal ∝ [RANKL] / [OPG]

When PTH is elevated, RANKL expression increases and OPG decreases, raising the ratio and promoting osteoclastogenesis. When PTH is low or absent, OPG predominates, and osteoclast activity diminishes.

Calcitriol — Intestinal Ca²⁺ Absorption

Calcitriol (1,25(OH)₂D₃) acts as a steroid hormone: it enters enterocytes of the duodenum, binds the intracellular vitamin D receptor (VDR), and the VDR–calcitriol complex heterodimerizes with the retinoid X receptor (RXR). This complex translocates to the nucleus and activates transcription of genes encoding calbindin-D₉ₖ (intracellular calcium shuttle), the apical calcium channel TRPV6, and the basolateral Ca²⁺-ATPase (PMCA1b). Together, these proteins enable transcellular calcium transport from gut lumen to blood, which accounts for the regulated, saturable component of intestinal calcium absorption.

CALCITRIOL SYNTHESIS PATHWAY

7-DHC → (UV-B in skin) → Vitamin D₃ → (25-hydroxylase in liver) → 25(OH)D₃ → (1α-hydroxylase in kidney, stimulated by PTH) → 1,25(OH)₂D₃

7-DHC = 7-dehydrocholesterol. Each hydroxylation step adds an −OH group. The final renal step is the regulated, rate-limiting conversion that PTH activates.

Calcitonin — Osteoclast Inhibition

Unlike PTH, calcitonin acts directly on osteoclasts, which express the calcitonin receptor (CTR), a G-protein-coupled receptor. Binding triggers cAMP-dependent retraction of the osteoclast's ruffled border, effectively halting resorption within minutes. Calcitonin also promotes renal excretion of both calcium and phosphate, providing a rapid — if clinically modest — hypocalcemic effect. While calcitonin's role is clearly important during periods of high calcium stress such as pregnancy and lactation, its overall contribution in adult males and non-pregnant females appears relatively minor compared to PTH.

💡

Pulsatile vs. Continuous PTH

An important clinical nuance: intermittent (pulsatile) PTH exposure is anabolic — it stimulates osteoblast activity and increases bone formation, which is the basis for teriparatide therapy in osteoporosis. In contrast, continuous PTH elevation (as in primary hyperparathyroidism) shifts the RANKL/OPG ratio persistently toward resorption, resulting in net bone loss. The same hormone can build or destroy bone depending on its temporal delivery pattern.

SECTION 5

Bone Remodeling Cycle — Cellular Details

Bone remodeling occurs at discrete anatomical sites called basic multicellular units (BMUs). Each BMU progresses through a sequence of phases — activation, resorption, reversal, formation, and quiescence — in a cycle lasting approximately 4–6 months in cortical bone. In healthy adults, roughly 5–10% of the skeleton is replaced each year through this process. The remodeling cycle is tightly coupled: signals released during resorption (such as TGF-β and IGF-1 freed from the degraded matrix) recruit osteoblast progenitors to the resorption pit, ensuring that formation follows resorption at the same site. Hormonal perturbations — sustained PTH excess, estrogen deficiency, or glucocorticoid therapy — can uncouple formation from resorption, leading to net bone loss.

The five phases of the bone remodeling cycle within a single BMU. Activation is initiated by osteocyte sensing of microdamage or hormonal cues (PTH). Resorption by multinucleated osteoclasts lasts 2–3 weeks and releases Ca²⁺ into the bloodstream. During the reversal phase, coupling factors released from the matrix recruit osteoblasts. Formation is the longest phase, requiring 4–6 months for osteoid deposition and mineralization. In quiescence, the bone surface is sealed by lining cells and some osteoblasts become embedded as osteocytes.

Cell Type	Origin	Primary Function	Key Markers
Osteoblast	Mesenchymal stem cell	Synthesizes osteoid (Type I collagen); initiates mineralization	Alkaline phosphatase (ALP), osteocalcin, RUNX2
Osteocyte	Terminally differentiated osteoblast	Mechanosensing via lacuno-canalicular network; produces sclerostin	DMP1, SOST (sclerostin gene), FGF23
Osteoclast	Hematopoietic (monocyte–macrophage lineage)	Resorbs bone via acid dissolution and enzymatic degradation	TRAP, cathepsin K, RANK
Lining cell	Quiescent osteoblast	Covers resting bone surfaces; may reactivate upon hormonal stimulation	Low ALP expression

Key bone cells involved in remodeling

SECTION 6

Worked Example — Tracing a Hypocalcemic Response

Consider a clinical scenario: a patient presents with a serum total calcium of 1.9 mmol/L (normal: 2.2–2.6 mmol/L). The patient's albumin is normal, ruling out pseudohypocalcemia. Walk through the expected physiological compensatory cascade and predict the laboratory findings you would expect if the compensatory mechanisms are intact.

Physiological Response to Hypocalcemia

1
Step 1 — Sensor Detection

The calcium-sensing receptor (CaSR) on parathyroid chief cells detects the fall in ionized Ca²⁺. At 1.9 mmol/L total calcium (≈ 0.95 mmol/L ionized, assuming ~50% ionized fraction), the CaSR's tonic inhibition of PTH secretion is relieved.

CaSR deactivation → immediate PTH release from preformed vesicles (seconds to minutes).
2
Step 2 — Rapid Renal Response

PTH acts on the thick ascending limb and distal convoluted tubule of the nephron. In the DCT, PTH activates apical TRPV5 calcium channels and basolateral Ca²⁺-ATPase, increasing tubular calcium reabsorption. Simultaneously, PTH inhibits the Na⁺/PO₄³⁻ cotransporter (NaPi-IIa) in the proximal tubule, causing phosphaturia.

Predicted labs: ↑ Ca²⁺ reabsorption (urine Ca²⁺ low), ↓ serum PO₄³⁻ (urine PO₄³⁻ high).
3
Step 3 — Calcitriol Synthesis

PTH upregulates 1α-hydroxylase (CYP27B1) in proximal tubule cells, converting circulating 25(OH)D₃ to active 1,25(OH)₂D₃ (calcitriol). This takes hours to days for full effect.

Predicted lab: ↑ serum 1,25(OH)₂D₃; 25(OH)D₃ may be normal or low depending on vitamin D stores.
4
Step 4 — Intestinal Calcium Absorption

Calcitriol binds VDR in duodenal enterocytes, upregulating TRPV6, calbindin-D₉ₖ, and PMCA1b. Over 1–2 days, the fraction of dietary calcium absorbed increases substantially, from perhaps 15–20% (passive-only) to 30–40% (passive + active transcellular transport).

Net intestinal Ca²⁺ absorption rises, contributing to plasma Ca²⁺ restoration.
5
Step 5 — Bone Resorption

Sustained PTH elevation shifts the RANKL/OPG ratio on osteoblasts, promoting osteoclast differentiation and activation. Osteoclastic resorption releases Ca²⁺ and PO₄³⁻ from hydroxyapatite into the extracellular fluid. Serum markers of bone resorption — such as C-terminal telopeptide (CTX) — would be expected to rise.

Bone-derived Ca²⁺ enters circulation; ↑ serum CTX, ↑ urine deoxypyridinoline.
6
Step 6 — Restoration of Setpoint

As plasma Ca²⁺ returns toward 2.2–2.6 mmol/L, the CaSR is re-engaged, suppressing further PTH release. The system settles at a new steady state. If the hypocalcemic stimulus was transient (e.g., a missed calcium-rich meal), the bone resorption signal diminishes and the skeleton is subsequently repaired during the formation phase of remodeling.

Plasma Ca²⁺ restored to normal range. Expected labs: PTH normalizes, phosphate normalizes, calcitriol returns to baseline.

SECTION 7

Clinical Disorders — When Homeostasis Fails

When the calcium homeostatic machinery breaks down, the clinical consequences can be severe and multisystemic. Disorders are broadly classified by whether plasma Ca²⁺ is too high (hypercalcemia) or too low (hypocalcemia), and by the underlying hormonal or end-organ defect. The table below contrasts common etiologies, their pathophysiological mechanisms, and expected laboratory profiles.

Disorder	Mechanism	Serum Ca²⁺	Serum PTH	Serum PO₄³⁻
Primary hyperparathyroidism	Autonomous PTH secretion (usually adenoma); unchecked bone resorption and renal Ca²⁺ retention	↑	↑ (inappropriately)	↓ or low-normal
Hypoparathyroidism	PTH deficiency (post-surgical, autoimmune); reduced bone resorption and Ca²⁺ reabsorption	↓	↓ or absent	↑
Vitamin D deficiency	Insufficient calcitriol → poor intestinal Ca²⁺ absorption → secondary ↑ PTH	↓ or low-normal	↑ (compensatory)	↓
Malignancy-associated hypercalcemia	Tumor secretes PTHrP or causes osteolytic metastases releasing Ca²⁺	↑↑	↓ (suppressed by Ca²⁺)	Variable
Chronic kidney disease (CKD)	↓ 1α-hydroxylase → ↓ calcitriol → ↓ Ca²⁺ absorption → secondary hyperparathyroidism; phosphate retention	↓	↑↑	↑↑

Common disorders of calcium homeostasis and their laboratory signatures

✦

KEY TAKEAWAY

When interpreting calcium labs, always assess PTH and phosphate together — they form a diagnostic signature. In primary hyperparathyroidism, the hallmark is high calcium with inappropriately high PTH (the gland ignores the high Ca²⁺). In malignancy-associated hypercalcemia, PTH is appropriately suppressed because the hypercalcemia is driven by a tumor product (PTHrP or osteolytic factors), not by the parathyroids. Distinguishing these patterns is one of the most common diagnostic exercises in internal medicine.

SECTION 8

Connections to Advanced Endocrine & Skeletal Biology

The classical model of calcium homeostasis — PTH, calcitonin, and calcitriol acting on bone, kidney, and gut — has been substantially enriched by modern discoveries. The skeleton is now recognized as an endocrine organ in its own right, secreting hormones that regulate phosphate metabolism, glucose homeostasis, and even male fertility. These emerging concepts bridge foundational physiology to frontier research.

Classical Concept	Advanced Extension
PTH–calcitriol axis raises Ca²⁺	FGF23–Klotho axis: osteocytes secrete FGF23 in response to high phosphate or calcitriol. FGF23 acts on the kidney to inhibit 1α-hydroxylase and promote phosphaturia, adding a bone-to-kidney endocrine loop that modulates vitamin D activation.
Bone is a structural and mineral scaffold	Osteocalcin as metabolic hormone: undercarboxylated osteocalcin released during resorption stimulates insulin secretion from β-cells and adiponectin from adipocytes, linking bone remodeling to glucose and energy metabolism (Karsenty, 2007).
Osteoclast inhibition by calcitonin	RANKL-targeted therapy (denosumab): a monoclonal antibody against RANKL mimics OPG, potently inhibiting osteoclastogenesis. Used clinically for osteoporosis and skeletal-related events in metastatic cancer.
Bone formation via osteoblasts	Wnt/sclerostin pathway: osteocytes secrete sclerostin (SOST gene), which inhibits Wnt signaling in osteoblasts, suppressing formation. Anti-sclerostin antibody (romosozumab) is a new anabolic therapy for severe osteoporosis.
Estrogen withdrawal causes osteoporosis	Estrogen modulates RANKL/OPG and osteocyte apoptosis: postmenopausal estrogen decline increases osteoblast RANKL expression and osteocyte apoptosis, accelerating remodeling with a resorption-dominant imbalance — the cellular basis of postmenopausal osteoporosis.

Classical vs. advanced concepts in bone-endocrine biology

These advanced concepts demonstrate that the skeleton participates in systemic endocrine networks well beyond calcium regulation. For students continuing into endocrinology, rheumatology, or nephrology, the FGF23–Klotho axis is particularly important: in CKD, FGF23 levels rise dramatically as a compensatory response to phosphate retention, and this chronic elevation is now recognized as an independent cardiovascular risk factor. Understanding these feedback loops at the molecular level is essential for interpreting the complex mineral and bone disorders seen in renal patients.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why osteoclasts, the cells that resorb bone, do not express PTH receptors directly. What advantage might this indirect signaling pathway (PTH → osteoblast → RANKL → osteoclast) provide over a direct PTH–osteoclast pathway?

Show answer

Osteoclasts derive from the monocyte–macrophage lineage, while osteoblasts derive from mesenchymal stem cells. The indirect pathway routes the resorption signal through the cells responsible for bone formation, enabling tight coupling between resorption and subsequent formation. When PTH activates osteoblasts, these cells simultaneously modulate RANKL and OPG, controlling osteoclast activity with nuance (e.g., the magnitude and duration of PTH exposure matters). This architecture ensures that resorption does not occur without the osteoblast lineage being 'aware,' facilitating the reversal-to-formation transition. A direct pathway would bypass this coupling mechanism, potentially leading to unchecked resorption without a reparative formation signal.

Question 2: BASIC CALCULATION

A patient's total serum calcium is 2.0 mmol/L and serum albumin is 30 g/L (normal: 40 g/L). Using the standard correction formula — corrected Ca²⁺ (mmol/L) = measured Ca²⁺ + 0.02 × (40 − albumin in g/L) — calculate the corrected calcium and determine whether the patient is truly hypocalcemic.

Show answer

Corrected Ca²⁺ = 2.0 + 0.02 × (40 − 30) = 2.0 + 0.02 × 10 = 2.0 + 0.2 = 2.2 mmol/L. The corrected calcium of 2.2 mmol/L falls at the lower boundary of the normal range (2.2–2.6 mmol/L), suggesting the patient is not significantly hypocalcemic — the low measured value was largely due to hypoalbuminemia reducing protein-bound calcium. This correction is clinically essential because roughly 40% of total serum calcium is bound to albumin, and low albumin artificially lowers the total without affecting the physiologically active ionized fraction.

Question 3: INTERMEDIATE

A patient with chronic kidney disease (CKD stage 4, GFR ≈ 20 mL/min) presents with the following labs: serum Ca²⁺ = 1.8 mmol/L, PO₄³⁻ = 2.5 mmol/L (high), PTH = 450 pg/mL (markedly elevated), 25(OH)D₃ = 60 nmol/L (sufficient). Explain the pathophysiological sequence that produces this lab pattern and identify which step in the calcitriol synthesis pathway is disrupted.

Show answer

In CKD, progressive nephron loss reduces the kidney's mass of 1α-hydroxylase enzyme, impairing conversion of 25(OH)D₃ to active 1,25(OH)₂D₃ (calcitriol) — the final, regulated step in the calcitriol synthesis pathway is disrupted. Despite adequate vitamin D stores (25(OH)D₃ = 60 nmol/L), calcitriol levels are low, reducing intestinal Ca²⁺ absorption and causing hypocalcemia. Simultaneously, reduced GFR impairs phosphate excretion, leading to hyperphosphatemia. Both low Ca²⁺ and high PO₄³⁻ stimulate the parathyroid glands, driving secondary hyperparathyroidism (PTH = 450 pg/mL). The elevated PTH represents an appropriate, compensatory response — unlike in primary hyperparathyroidism, where PTH secretion is autonomous. Over time, persistent parathyroid stimulation can lead to glandular hyperplasia and eventually tertiary hyperparathyroidism.

Question 4: APPLIED

A postmenopausal woman with osteoporosis is started on teriparatide (recombinant PTH 1-34), given as a once-daily subcutaneous injection. Her friend, who has primary hyperparathyroidism with chronically elevated PTH, has significant bone loss. Explain the paradox: why does exogenous PTH build bone in one patient and chronic endogenous PTH destroy bone in the other? Reference the RANKL/OPG system in your answer.

Show answer

The key variable is the temporal pattern of PTH exposure. Teriparatide delivers intermittent, pulsatile PTH — a single daily injection produces a peak followed by rapid clearance. This pulsatile pattern preferentially stimulates osteoblast proliferation and survival, upregulates Wnt signaling, and transiently increases RANKL but also boosts OPG and other anabolic factors, resulting in net formation exceeding resorption (a positive bone balance). In contrast, the continuously elevated PTH in primary hyperparathyroidism sustains a high RANKL/OPG ratio chronically, driving persistent osteoclastogenesis and resorption that outpaces the formation arm of remodeling. Molecular studies have shown that continuous PTH exposure increases osteoblast apoptosis and blunts the anabolic Wnt response, while intermittent exposure enhances osteoblast survival. This dual nature of PTH — anabolic when pulsatile, catabolic when continuous — is one of the most clinically important nuances in bone endocrinology.

Question 5: CRITICAL THINKING

A research group discovers that osteocyte-specific knockout of the SOST gene (which encodes sclerostin) in mice leads to dramatically increased bone mass. They propose developing an anti-sclerostin antibody for osteoporosis. Predict at least three physiological or clinical considerations they would need to address, referencing the interplay between the Wnt pathway, RANKL/OPG, calcium homeostasis, and potential off-target effects on mineral balance.

Show answer

First, sclerostin is a negative regulator of Wnt signaling in osteoblasts; blocking it would massively upregulate bone formation. However, increased formation requires calcium and phosphate deposition into new matrix, potentially causing transient hypocalcemia and triggering compensatory PTH elevation — the researchers would need to monitor mineral balance and potentially supplement calcium and vitamin D. Second, enhanced osteoblast activity alters the RANKL/OPG ratio: while initial formation dominates, the coupled remodeling system may eventually increase resorption as newly formed bone is remodeled, creating a 'rebound' bone loss risk if the antibody is discontinued (this has been observed clinically with romosozumab). Third, Wnt signaling operates in many tissues — cardiovascular, neural, intestinal — raising concerns about off-target effects, particularly a theoretical cardiovascular risk from ectopic calcification promotion or effects on vascular smooth muscle, which was a safety signal in early romosozumab trials. Additionally, the researchers should consider whether supra-physiological bone density, while mechanically strong, might produce abnormally brittle bone if the collagen-mineral ratio is altered (as seen in some high-bone-mass conditions like osteopetrosis). These considerations illustrate how targeted skeletal therapies inevitably interface with systemic mineral homeostasis and non-skeletal biology.

SUMMARY

Calcium Homeostasis — Integrated Review

Summary

Calcium homeostasis is governed by a negative feedback system centered on the calcium-sensing receptor (CaSR) of the parathyroid glands. When plasma Ca²⁺ falls below the setpoint of approximately 2.2–2.6 mmol/L, PTH is released and acts on three effector organs: bone (promoting osteoclast-mediated resorption via the RANKL/OPG pathway), kidney (increasing Ca²⁺ reabsorption and stimulating 1α-hydroxylase to produce calcitriol), and intestine (where calcitriol drives transcellular Ca²⁺ absorption via TRPV6 and calbindin-D₉ₖ). Calcitonin from thyroid C cells provides a counterbalancing hypocalcemic signal by directly inhibiting osteoclasts, though its clinical significance in adult humans is modest.

Bone remodeling occurs continuously at basic multicellular units (BMUs) through coupled cycles of osteoclast resorption and osteoblast formation. Hormonal imbalances — such as primary hyperparathyroidism, vitamin D deficiency, or CKD-related secondary hyperparathyroidism — uncouple this balance, producing clinically recognizable laboratory patterns. Advanced concepts including the FGF23–Klotho axis, osteocalcin as a metabolic hormone, and Wnt/sclerostin signaling reveal the skeleton as a fully integrated endocrine organ, with implications for pharmacology (teriparatide, denosumab, romosozumab) and for understanding the mineral bone disorders of chronic kidney disease.